Business Wire

Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy

Share

Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of Andrew Dickinson to Executive Vice President, Corporate Development and Strategy, with responsibility for Gilead’s corporate development, alliance management, competitive intelligence, and corporate strategy and planning functions, effective immediately. Mr. Dickinson will become a member of Gilead’s senior leadership team. The company also announced that Martin Silverstein, Executive Vice President, Strategy, has decided to leave Gilead at the end of August to return to the East Coast.

Mr. Dickinson joined Gilead in 2016 as Senior Vice President, Corporate Development. He led the acquisitions of Kite Pharma, Inc. and Cell Design Labs, Inc., and has been instrumental in reshaping Gilead’s approach to corporate development, increasing the volume and types of agreements that the company has entered into during his tenure. Prior to joining Gilead, Mr. Dickinson served as Global Co-Head of Healthcare Investment Banking for Lazard. At Lazard, he advised on numerous, industry-defining merger and acquisition transactions, as well as many other strategic matters across the biopharmaceutical industry. Mr. Dickinson received his bachelor’s degree in molecular, cellular and developmental biology from the University of Colorado and his law degree from Loyola University Chicago.

“Andy has brought to Gilead vision, creativity and leadership, fundamentally changing the way that we assess and execute acquisitions and partnerships as an organization,” said John F. Milligan, PhD, President and Chief Executive Officer of Gilead. “His deep understanding of the industry has helped guide Gilead’s strategy and will be critical to our future success.”

Dr. Silverstein will remain at Gilead through the end of August, working with Mr. Dickinson and other leaders to transition his duties.

“I’m grateful to Marty for his exceptional work to strengthen Gilead’s strategic planning and vision, and ensure that we are well-positioned for future growth, as we seek to bring the next generation of medicines forward for patients with unmet medical needs,” said Dr. Milligan. “We understand his decision to eliminate the bicoastal schedule he has kept since joining Gilead and be closer to his family, and wish him the very best in the next phase of his career.”

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties, and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company’s website at  www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contact information

Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
or
Media
Amy Flood, 650-522-5643

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Business Figures for the First Half of 2019: Sartorius Continues Double-digit Growth19.7.2019 05:00:00 CESTPress release

Sartorius, a leading international partner of biopharmaceutical research and the industry, grew strongly in the first half of 2019, recording double-digit increases in sales revenue, order intake and earnings. Given these results and continued positive prospects for the Bioprocess Solutions Division for the second half, management has raised its full-year targets. “We are very pleased on the whole with business progress in the first half, though both divisions showed different growth dynamics,” said Executive Board Chairman and CEO Dr. Joachim Kreuzburg. “While growth in the lab business slowed down due to the currently uncertain and softer economic environment, especially at the end of the second quarter, momentum for Bioprocess Solutions has remained unchanged at a very high level. In view of further development, we are very confident and expect full-year sales growth of 10% to 14% instead of our previously forecasted 7% to 11%.” Consolidated sales revenue in constant currencies rose

Quanergy and Chery Established Partnership to Propel a New Era of Autonomous Vehicles and Smart Cities18.7.2019 19:00:00 CESTPress release

Quanergy Systems, Inc., a leading provider of LiDAR (Light Detection and Ranging) sensors and smart sensing solutions, announced a partnership with Chery Automobile, one of the largest automotive manufacturers in China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190718005616/en/ Quanergy and Chery Established Partnership to Propel a New Era of Autonomous Vehicles and Smart Cities (Graphic: Business Wire) On June 20th, 2019, Chery unveiled the logo of its new brand Chery Lion, and announced its strategic plan of working with selected partners to solve technological challenges across the ecosystem. Quanergy signed on to Chery Lion’s Smart Partner Program as the LiDAR partner, to focus efforts on advancing autonomous driving and smart cities in China. “As the autonomous vehicle industry matures, it is imperative to build an ecosystem that supports a transportation network with reliable solutions.” said Dr. Yong Huang, Vice

LTI USD Revenue Growth up 11.5% YoY; Digital Revenues at 39%18.7.2019 16:08:00 CESTPress release

Larsen & Toubro Infotech (BSE: 540005, NSE: LTI), a global technology consulting and digital solutions company, announced its Q1 FY20 results today. Q1 FY20 In US Dollars: Revenue at USD 356.5 million; growth of 0.8% QoQ and 11.5% YoY Constant Currency Revenue growth of 1.0% QoQ and 12.9% YoY In Indian Rupees: Revenue at Rs 24,849 million; growth was flat QoQ and 15.3% YoY Net Income at Rs 3,557 million; growth of (6.1%) QoQ and (1.5%) YoY “We delivered 12.9% YoY revenue growth in constant currency driven by Digital Services that now make up 39% of our revenues. We also won a large deal by opening a new client logo in Insurance vertical with net-new TCV of US$44m. We are also pleased to welcome Lymbyc to LTI family. Lymbyc is a specialist AI, machine learning, and advanced analytics company. The acquisition further strengthens LTI’s Mosaic platform and our fast-growing digital and analytics offerings.” - Sanjay Jalona, Chief Executive Officer & Managing Director, LTI Recent Deal Wins A

Moody’s Analytics Wins Wholesale Modelling Software of the Year at Risk Technology Awards18.7.2019 15:30:00 CESTPress release

Moody’s Analytics, a global provider of financial intelligence, has won Wholesale Modelling Software of the Year in the 2019 Risk Technology Awards. It’s one of six categories won, spanning finance, accounting, regulatory, and credit functions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190718005512/en/ A suite of integrated Moody’s Analytics offerings contributed to this win, including the CreditEdge™ solution, which delivers a leading probability of default model and advanced analytics for managing the daily credit risk of more than 60,000 public firms and sovereigns. Our RiskCalc™ credit scoring platform helps clients assess the credit risk of private firms, commercial banks, project finance projects, and insurance companies. The CMM™ solution combines property performance forecasts with commercial mortgage fundamentals to assess default and recovery risk for commercial real estate properties. The new CAP™ platform ex

Fabasoft is a “Strong Performer” for Cloud Content Platforms, Q3 201918.7.2019 14:39:00 CESTPress release

Fabasoft, a leading European provider of cloud solutions, was invited by Forrester to be part of the independent evaluation “The Forrester New Wave™: Cloud Content Platforms – Multitenant SaaS, Q3 2019.”* Upon conclusion of the evaluation, Fabasoft was positioned in the “Strong Performers” group. The research and consulting firm Forrester Research Inc. has evaluated 13 top cloud content platforms based on 10 transparent criteria relating to current offering, strategy, and market presence. The report is based on an analysis of data from product presentations, a survey, and customer interviews. “We are proud that with Fabasoft Cloud, we have been positioned in the New Wave as a strong performer by a leading international analyst firm,” says Andreas Dangl, Business Unit Executive Cloud Services at Fabasoft. “We are especially pleased that Fabasoft is the only European cloud provider in this field. This makes it clear to us that Fabasoft Cloud is the best digitalization platform for large-

Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 201918.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that new data from the company’s HIV research and development programs will be presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City from July 21-24. Fifteen abstracts, along with community-focused symposia and workshops, reflect Gilead’s ongoing commitment to scientific innovation, a key pillar to addressing unmet and evolving medical needs in HIV. “Gilead’s scientific discovery has helped transform both HIV treatment and prevention and we are committed to advancing the next generation of therapies to improve the care of people and communities impacted by this disease,” said John McHutchison, AO, MD, Chief Scientific Officer, Head of Research & Development, Gilead Sciences. “Our data at this year’s meeting include exciting progress in our HIV prevention, treatment and cure programs, which together are helping to advance the field of HIV toward the ultimate goal of ending the